MARIPOSA-2: How Baseline Mechanisms of Osimertinib Resistance Influence Outcomes in NSCLC
How Is Oligoprogressive Disease Managed in Patients With EGFR-Positive NSCLC?
Lung Cancer Risk: The Role of Family History and Germline Genetic Alterations
AI-Based Lung Cancer Screening: Molly Li, MBBS, Shares Insights From the LC-SHIELD Study
FDA Grants Approval of Taletrectinib for ROS1-Positive NSCLC
TROP2-Targeting Boosters: Dr. Poznanski Shares Preclinical Data in NSCLC at ASCO 2025